Analgesic and Antiallodynic Effects of 4-Fluoro-N-(4-Sulfamoylbenzyl) Benzene Sulfonamide in a Murine Model of Pain.
Administration, Oral
Analgesics
/ administration & dosage
Animals
Anti-Inflammatory Agents
/ administration & dosage
Diabetes Mellitus, Experimental
/ chemically induced
Diabetic Neuropathies
/ chemically induced
Disease Models, Animal
Dose-Response Relationship, Drug
Hyperalgesia
/ chemically induced
Male
Mice
Mice, Inbred BALB C
Molecular Structure
Pain
/ drug therapy
Streptozocin
Structure-Activity Relationship
antinociception
diabetes mellitus; DM
neuropathic pain
streptozotocin; STZ
sulfonamides
von Frey filaments
Journal
Drug design, development and therapy
ISSN: 1177-8881
Titre abrégé: Drug Des Devel Ther
Pays: New Zealand
ID NLM: 101475745
Informations de publication
Date de publication:
2020
2020
Historique:
received:
28
06
2020
accepted:
10
09
2020
entrez:
5
11
2020
pubmed:
6
11
2020
medline:
25
8
2021
Statut:
epublish
Résumé
Physical, chemical, thermal injuries along with infectious diseases lead to acute pain with associated inflammation, being the primary cause of hospital visits. Moreover, neuropathic pain associated with diabetes is a serious chronic disease leading to high morbidity and poor quality of life. Earlier multiple sulphonamides have been reported to have an antinociceptive and antiallodynic profile. 4-Fluoro-N-(4-sulfamoylbenzyl) Benzene Sulfonamide (4-FBS), a synthetic sulfonamide with reported carbonic anhydrase inhibitory activity, was investigated for its potential effects in mice model of acute and diabetic neuropathic pain. 4-FBS was given orally (p.o.) one hour before the test and then mice were screened for antinociceptive activity by using the tail immersion test, which showed significant antinociceptive effect at both 20 and 40 mg/kg doses. To explore the possible mechanisms, thermal analgesia of 4-FBS was reversed by the 5HT These findings are significant and promising while further studies are warranted to explore the exact molecular mechanism and the potential of 4-FBS in diabetic neuropathic pain.
Identifiants
pubmed: 33149549
doi: 10.2147/DDDT.S269777
pii: 269777
pmc: PMC7602919
doi:
Substances chimiques
Analgesics
0
Anti-Inflammatory Agents
0
Streptozocin
5W494URQ81
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4511-4518Informations de copyright
© 2020 Ur Rehman et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
J Peripher Nerv Syst. 2014 Jun;19(2):77-87
pubmed: 24934510
Bioorg Med Chem Lett. 2017 Jun 15;27(12):2683-2688
pubmed: 28465103
Pain. 2020 Feb;161(2):405-415
pubmed: 31634341
Diabetes Care. 2017 Jan;40(1):136-154
pubmed: 27999003
J Neurosci Methods. 1994 Jul;53(1):55-63
pubmed: 7990513
J Pharm Pharm Sci. 2013;16(5):821-47
pubmed: 24393558
Pain. 2010 Feb;148(2):302-308
pubmed: 20007010
Anesth Analg. 2002 Jun;94(6):1553-7, table of contents
pubmed: 12032025
Handb Clin Neurol. 2013;115:591-606
pubmed: 23931804
Diabetol Metab Syndr. 2012 May 29;4(1):21
pubmed: 22642973
Anesthesiology. 2018 Jun;128(6):1220-1236
pubmed: 29601322
Cochrane Database Syst Rev. 2017 May 22;5:CD011669
pubmed: 28530786
Curr Protoc Pharmacol. 2015 Sep 01;70:5.47.1-5.47.20
pubmed: 26331889
Phytomedicine. 2008 Apr;15(4):301-5
pubmed: 17689231
Expert Opin Ther Pat. 2013;23(6):681-91
pubmed: 23488823
Lancet Neurol. 2012 Jun;11(6):521-34
pubmed: 22608666
Science. 1976 Jul 30;193(4251):415-7
pubmed: 180605
Expert Opin Ther Pat. 2013;23(6):717-24
pubmed: 23514045
Prog Neurobiol. 2000 Jun;61(2):169-203
pubmed: 10704997
J Pharm Pharmacol. 2020 Jul;72(7):863-872
pubmed: 32067247
Expert Rev Neurother. 2008 May;8(5):781-97
pubmed: 18457535
Curr Pharm Des. 2015;21(13):1723-40
pubmed: 25412650
Neuropharmacology. 2002 Nov;43(6):945-58
pubmed: 12423664
Diabetes. 2007 Jun;56(6):1569-76
pubmed: 17287466
Angew Chem Int Ed Engl. 2014 Apr 14;53(16):4231-5
pubmed: 24623670
J Pain. 2014 Apr;15(4):395-406
pubmed: 24412803
Exp Clin Psychopharmacol. 2008 Oct;16(5):405-16
pubmed: 18837637
Br J Anaesth. 2002 May;88(5):679-84
pubmed: 12067006
Nat Clin Pract Neurol. 2007 Jun;3(6):331-40
pubmed: 17549059
Postgrad Med. 2019 Sep;131(7):438-444
pubmed: 31482756
Pain. 2011 Mar;152(3 Suppl):S2-S15
pubmed: 20961685
Bioorg Med Chem. 2015 May 15;23(10):2435-44
pubmed: 25865133
Diabetes Care. 2010 Oct;33(10):2285-93
pubmed: 20876709
J Neurosci. 2018 Jan 10;38(2):379-397
pubmed: 29167404
Burns. 2014 Jun;40(4):759-71
pubmed: 24290856
Diabetes Care. 2011 Oct;34(10):2220-4
pubmed: 21852677
Neuropharmacology. 2005 Jun;48(7):1021-34
pubmed: 15857629
J Pharmacol Methods. 1989 Mar;21(1):21-31
pubmed: 2704245
Anesth Analg. 2017 Jan;124(1):44-51
pubmed: 27861439
Eur J Pain. 2016 Oct;20(9):1423-32
pubmed: 27271035
BMC Complement Altern Med. 2016 Feb 24;16:77
pubmed: 26912265
Mol Pharmacol. 2006 Oct;70(4):1246-54
pubmed: 16868181
Rev Pain. 2011 Sep;5(3):13-7
pubmed: 26526458
Expert Rev Neurother. 2016 Aug;16(8):961-8
pubmed: 27211329